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Abstract
Background: CD133 was detected in several types of cancers including hepatocellular carcinoma (HCC),
which raised the possibility of stem cell origin in a subset of cancers. However, reappearance of embryonic
markers in de-differentiated malignant cells was commonly observed. It remained to be elucidated whether
CD133-positive HCCs were indeed of stem cell origin or they were just a group of poorly differentiated
cells acquiring an embryonic marker. The aim of this study was to investigate the significance of CD133
expression in HCC in an area endemic for hepatitis B virus (HBV) infection to gain insights on this issue.
Methods: 154 HCC patients receiving total removal of HCCs were included. 104 of them (67.5%) were
positive for HBV infection. The cancerous and adjacent non-cancerous liver tissues were subjected for
Western blot and immunohistochemistry analysis for CD133 expression. The data were correlated with
clinical parameters, patient survivals, and p53 expression.
Results: Of 154 patients, 24 (15.6%) had CD133 expression in HCC. Univariate and multivariate logistic
regression analysis revealed that CD133 expression was negatively correlated with the presence of
hepatitis B surface antigen (HBsAg). The unadjusted and adjusted odds ratios were 0.337 (95%CI 0.126 -
0.890) and 0.084 (95%CI 0.010 - 0.707), respectively. On the other hand, p53 expression was positively
associated with the presence of HBsAg in univariate analysis. The unadjusted odds ratio was 4.203 (95%CI
1.110 - 18.673). Survival analysis indicated that both CD133 and p53 expression in HCC predicted poor
disease-free survival (P = 0.009 and 0.001, respectively), whereas only CD133 expression predicted poor
overall survival (P = 0.001). Cox proportional hazard model showed that p53 and CD133 expression were
two independent predictors for disease-free survival. The hazard ratios were 1.697 (95% CI 1.318 - 2.185)
and 2.559 (95% CI 1.519 - 4.313), respectively (P < 0.001 for both).
Conclusion: In area where HBV infection accounts for the major attributive risk of HCC, CD133
expression in HCC was negatively associated with the presence of HBsAg, implicating a non-viral origin of
CD133-positive HCC. Additionally, CD133 expression predicted poor disease-free survival independently
of p53 expression, arguing for two distinguishable hepatocarcinogenesis pathways.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
monly diagnosed solid cancer as well as the third most
common cause of cancer-related death in the world [1].
The etiology of HCC is multifactorial, including chronic
hepatitis B virus (HBV) infection, chronic hepatitis C virus
(HCV) infection, alcoholic liver disease, and others [2,3].
In areas where chronic hepatitis B is highly prevalent, such
as Southeast Asia and sub-Saharan Africa, correspond-
ingly higher incidence of HCC is found [4]. In contrast, in
Western countries, where chronic hepatitis C and alco-
holic liver disease account for the major attributable risk,
lower prevalence of HCC is observed. Over the past two
decades, the incidence of HCC is rising in Western world,
possibly due to increased incidence of HCV infection [5].
Other risk factors include old age, male gender, underly-
ing chronic liver diseases, and most importantly, liver cir-
rhosis [6]. Aflatoxin exposure has also been linked to
development of HCC in some areas [7-10]. A single muta-
tion in codon 249 of p53 is frequently seen in this sub-
group [9,10]. Because of the multifactorial etiology and
heterogeneous nature of the diseases, the key molecular
pathways leading to hepatocarcinogenesis remained illu-
sive. With the help of advanced technologies in genomic
medicine, it is discovered that hepatocarcinogenesis
involved not only multiple steps of molecular events but
also heterogeneous cellular pathways [11-13]. At this
stage, it is pivotal to identify major subpopulations of
HCC, of which the oncogenic pathways are better defined
so that a specific targeted therapeutic modality can be
devised.
CD133 is a human homologue of mouse Prominin-1, a
five-transmembrane cell surface glycoprotein [14-16]. It is
expressed in a subpopulation of the CD34+ hematopoietic
stem cells derived from fetal liver or bone marrow [17,18].
CD133 has been detected in neuroepithelial cells, embry-
onic epithelial cells and adult immature epithelial cells
[19-21]. On the other hand, CD133 is expressed in several
types of tumor tissues, including acute myeloid leukemia,
glioblastoma, ependymoma and prostate cancer [22-29].
It is hypothesized that cancer can be originated and main-
tained by a subset of cancer stem cells [30,31]. Recently,
CD133 was detected in HCC cell lines as well as some
human HCC tissues, suggesting a stem cell origin [32-34].
Additionally, CD133 expression in HCC is associated
with poor prognosis [35,36]. In Southeast Asia, however,
the most important etiology for HCC is HBV infection. It
is unclear whether cancer stem cells play a role in HBV-
related hepatocarcinogenesis. In the present study, we
investigated the clinicopathological significance of
CD133 expression in HCC in an area endemic for HBV
infection. Additionally, we examined whether CD133
expression associated with p53 over-expression in HCC,
another factor associated with poor prognosis [37,38].
Methods
Patients
This study was conducted under approval of the institu-
tional review board, Chang Gung Medical Center. Under
informed consent, 154 HCC patients receiving total
removal of liver tumors from July 1998 to Aug 2005 in
Chang Gung Medical Center, Taiwan, were included. All
samples were frozen to -70°C immediately after surgical
resection and stored in Tissue Bank, Chang Gung Medical
Center until used. The following clinicopathological data
were retrospectively reviewed: gender, age, HBV surface
antigen (HBsAg), antibody against HCV (anti-HCV), liver
cirrhosis status, alcoholism, Edmonson's histology grad-
ing, microvascular invasion, tumor capsule, number of
tumor, microsatellites, largest tumor size, portal vein
invasion, presence of ascites on surgery, alpha-fetoprotein
(AFP), albumin, bilirubin, prothrombin time, creatinine,
aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), the date of surgical resection, the date of
tumor recurrence or metastasis, and the date of last fol-
low-up or HCC related death.
Preoperative diagnosis of HCC was made by one of the
following methods: echo-guided liver biopsy, fine needle
aspiration cytology, high AFP level (> 200 ng/mL) plus at
least one dynamic imaging studies (dynamic computed
tomography or magnetic resonance imaging), or two
dynamic imaging studies plus angiography (if AFP < 200
ng/mL). Tumors were totally removed with a safety-mar-
gin of > 1 cm. Post-operative follow-up was performed by
ultrasonography, chest X-ray, AFP, and blood biochemis-
try every 1 to 3 months in the first year and 3 to 6 months
thereafter. Abnormal findings were verified by computed
tomography or magnetic resonance imaging. Intrahepatic
recurrence was verified by use of the aforementioned cri-
teria. Extrahepatic recurrence was verified by biopsy, aspi-
ration cytology, computed tomography or magnetic
resonance imaging study dependent on the location of the
lesions as well as the condition of the patients.
HBsAg was measured by a radioimmunoassay (Ausria-II,
HBsAg-RIA, Abbott Laboratories, North Chicago, IL).
Anti-HCV was measured by a third-generation enzyme
immunoassay (HCV EIA III; Abbott Laboratories).
Western blot analysis
Protein was extracted from the cancerous and adjacent
non-cancerous tissues with a commercial kit (T-PER Tis-
sue Protein Extraction Reagent, Thermo Fisher Scientific
Inc., Rockford, IL). After addition of a cocktail protease
inhibitor mix (Halt Protease Inhibitor Cocktail Kit,
Thermo Fisher Scientific Inc., Rockford, IL), the samples
were stored at -80°C. After sodium dodecyl sulfate poly-
acrylamide gel electrophoresis, immunoblot was carried
out by use of a primary mouse anti-human CD133 anti-BMC Cancer 2009, 9:324 http://www.biomedcentral.com/1471-2407/9/324
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body (Miltenyi Biotec GmbH, Bergisch Gladbach,
Gemany) in a 1 to 300 dilution for detection of CD133,
or a primary rabbit anti-human p53 antibody (Abcam,
Cambridge, UK) in a 1 to 200 dilution for detection of
p53. After incubation with a secondary anti-mouse or
anti-rabbit antibody, HRP conjugated (Leinco Technolo-
gies Inc., St. Louis, MO), the membrane was developed in
chemiluminescent detection reagents (ECL Plus, GE
Healthcare, Piscataway, NJ) and the signal was quantified
by densitometry. Subsequently, the same membrane was
stripped and re-probed with a primary mouse anti-human
actin monoclonal antibody (Abcam, Cambridge, UK) in a
1 to 5,000 dilution for detection of actin.
Immunohistochemistry
Liver specimens were fixed in 10% formaldehyde and
embedded in paraffin. Five-micrometer paraffin sections
were mounted on poly-L-lysine-coated slides for immu-
nohistochemistry. After de-paraffinization in xylene, the
sections were rehydrated through graded ethanol. Hepa-
tocyte expression of CD133 was assessed by the avidin-
biotin immunoperoxidase method. The sections were
incubated in PBS containing 5% of hydrogen peroxide for
15 minutes and were subsequently washed twice (5 min-
utes each) in PBS containing 0.025% Triton X-100 (Sigma
Chemical Co., St. Louis, MO). The tissue sections were
then incubated with 3% of bovine serum albumin and
10% of normal goat serum for 30 minutes, followed by a
1:500 dilution of the same mouse antibody against
human CD133 at 37°C for 1 hour. After washed with
phosphate-buffered saline (PBS; 0.1 M, pH 7.4), the sec-
tions were subsequently incubated with biotin-conju-
gated goat anti-mouse immunoglobulins (Jackson
Immunoresearch Lab., West Grove, PA) at a 1:400 dilu-
tion for 40 minutes. After rinsed with PBS, sections were
treated with avidin-biotin complex (Vectastain Elite ABC
Kit, Vector Labs, CA) for 30 minutes and then incubated
in a diaminobenzidine solution (DAB, Vector Labs, CA)
for 1 minute. Nuclear counterstaining was performed
with hematoxylin.
Real-time RT-PCR for CD133 mRNA quantification
Total RNA was isolated from both cancerous and non-
cancerous liver tissues using TRI reagent (Molecular
Research Center, Inc., Cincinnati, OH) according to the
manufacturer's instructions. To eliminate contaminated
DNA, the extracted RNA was dissolved in diethylpyrocar-
bonate-treated water containing 10 mmol/l of MgCl2 and
incubated with 100 μg/ml of RNase-free DNase I for 30
min at 37°C. EDTA was added to a final concentration of
30 mmol/l, and the mixture was heated at 95°C for 5 min
to stop the reaction. Reverse transcription was performed
by use of random primers. The primers for PCR detection
of CD133 cDNA were P1, 5'-TTTCAAGGACTT-
GCGAACTCTCTTGA-3' (nt. 776-801, sense) and P2, 5'-
GAACAGGGATGATGTTGGGTCTCA (nt. 942-919, anti-
sense). A fragment of amplified cDNA was inserted into
the pRC2.1-TOPO vector (Invitrogen, Carlsbad, CA) and
verified by DNA sequencing (CEQ 2000, Beckman Instru-
ments Inc., Fullerton, CA). As a control, a fragment of β-
actin cDNA flanked by PA1, 5'-CACCAACTGGGACGA-
CATGG-3' (nt. 301-320, sense), and PA2, 5'-AGGATCT-
TCATGAGGTAGTC-3' (nt. 651-532, antisense), was
amplified by RT-PCR and cloned into pRC2.1-TOPO.
The method of real-time PCR was described previously
[39]. Briefly, CD133 RNA and β-actin RNA fragments
were generated by in vitro transcription using the MEGAs-
cript T7 kit (Ambion Inc., Austin, TA). The RNA product
was thus dilated serially (10-fold) to generate a set of
standards containing 106 to 101 copies. Real-time PCR was
subsequently performed in LightCycler (Roche Diagnos-
tics Corporation, IN). The copy numbers of these two
RNA species derived from both the cancerous and non-
cancerous tissues had to fall into the standard curves, oth-
erwise both were diluted 10- and 100-fold in parallel and
the assays were repeated. All data were obtained from two
independent measurements.
Statistical analysis
Correlation between the CD133 or p53 expression and
clinicopathological parameters was conducted by use of
Fisher's exact test or Chi-square test (for dichotomy data)
and student's T test or linear regression analysis (for para-
metric data). Adjusted odds ratios (OR) were calculated
using multivariate logistic regression analysis. Overall sur-
vival was calculated from the date of diagnosis to the date
of death or last follow-up. Disease-free survival was meas-
ured from the date of diagnosis to the date of recurrence,
metastasis, death or last follow-up. The Kaplan-Meier
method was used to estimate the survival probability, and
the log-rank test was used to compare the survival curves
between groups. Independent predictive factors affecting
survival were analyzed by the Cox multivariate propor-
tional hazards model. P < 0.05 was considered statistically
significant. Statistical analysis was conducted by use of
SPSS (version 13.0).
Results
Western blot and immunohistochemistry analysis of 
CD133 expression in HCC
One hundred and fifty four patients, 40 females and 114
males, were included in this study. The basic clinical data
were listed in Table 1. In females, HBsAg and anti-HCV
were detected in about half of them (52.5% and 45.0%,
respectively). In contrast, in males, HBsAg was detected in
a higher proportion of patients (72.8%), whereas anti-
HCV was detected in a lower proportion of patients
(21.1%). A significantly higher proportion of males had
documented alcoholic history. Of 154 patients, 14 (9.1%)BMC Cancer 2009, 9:324 http://www.biomedcentral.com/1471-2407/9/324
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had no known etiology for HCC. Interestingly, 8 of these
14 patients (57.1%) had diabetes. All patients positive for
HBsAg were chronic carrier and the infection occurred
before 30 years of age. All patients were negative for serum
HBV e antigen (HBeAg). None of these patients had
received antiviral therapy prior to the diagnosis of HCC.
The cancerous and non-cancerous liver tissues were sub-
jected for western blot analysis to detect CD133 expres-
sion (Figure 1). Three expression patterns were found.
CD133 could be undetectable in both cancerous and non-
cancerous tissues (Figure 1A, upper panel), a small
amount of CD133 could be detected in non-cancerous tis-
sues but not in cancerous tissues (Figure 1A, lower panel)
or alternatively, a significant amount of CD133 was
detected in cancerous tissues (Figure 1B). The latter pat-
tern was observed in 24 patients.
Immunohistochemistry analysis was subsequently per-
formed. It was discovered that in the 24 patients positive
for CD133 expression in HCC, CD133 was mostly accu-
mulated as patches with granular appearance in the cyto-
plasm of a few scattered malignant hepatocytes (Figure 2).
In a particular patient, who had the highest amount of
CD133 expression in HCC (Figure 1B, patient-16),
CD133 was detected in the margins of vesicles in a great
proportion of cells (Figure 3). Additionally, marked fatty
metamorphosis was observed. This patient was negative
for serum HBsAg and anti-HCV.
Real-time PCR assay for CD133 mRNA
For samples negative for CD133 expression by western
blot analysis, the CD133 mRNA level was either undetec-
table or < 102 copies per 105 copies of β-actin mRNA. For
non-cancerous tissues expressing a small amount of
CD133 (Figure 1A, lower panel), the CD133 mRNA level
was 102.3 ± 0.4 to 104.1 ± 0.6 copies per 105 copies of β-actin
Table 1: Basic clinical characterization of patients included





Age (years) 57.5 ± 13.2 55.8 ± 15.5 0.545
Etiology
HBsAg (positive) 21 (52.5%) 83 (72.8%) 0.030
Anti-HCV (positive) 18 (45.0%) 24 (21.1%) 0.007
Alcoholism (yes) 4 (10.0%) 39 (34.2%) 0.004
Unknown causea 5 (12.5%) 9 (7.9%) 0.359







Tumor size (Diameter, cm) 7.0 ± 4.8 6.8 ± 4.7 0.826
Ascites (yes) 1 (2.5%) 13 (11.4%) 0.116
aDiabetes was found in 3 females and 5 males, respectively
bComparison between patients with tumor number  2 and those with tumor number > 2.
Western blot analysis of CD133 in paired cancerous (T) and  adjacent non-cancerous (N) liver tissues Figure 1
Western blot analysis of CD133 in paired cancerous 
(T) and adjacent non-cancerous (N) liver tissues. (A) 
CD133 was undetectable in the cancerous tissues. In some 
patients, a small amount of CD133 was detected in the non-
cancerous parts (lower panel). (B) CD133 was detected in 
the cancerous liver tissues.BMC Cancer 2009, 9:324 http://www.biomedcentral.com/1471-2407/9/324
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Immunohistochemistry analysis of CD133 expression in HCCs Figure 2
Immunohistochemistry analysis of CD133 expression in HCCs. CD133 was detected by avidin-biotin immunoperoxi-
dase method. Nuclei were counterstained by hematoxylin. Original magnification, 400×. Two HCC samples negative for 
CD133 expression served as negative controls (bottom panel).BMC Cancer 2009, 9:324 http://www.biomedcentral.com/1471-2407/9/324
Page 6 of 11
(page number not for citation purposes)
mRNA. For cancerous tissues positive for CD133 by west-
ern blot analysis (Figure 1B), the CD133 mRNA level was
102.5 ±  0.5 to 106.1 ±  0.9 copies per 105 copies of β-actin
mRNA.
CD133 expression in HCC is negatively associated with the 
presence of HBsAg
The clinicopathological data in patients with CD133
expression in HCC (n = 24) were compared with those
without CD133 expression in HCC (n = 130) (Table 2).
Among all factors compared, only the presence of HBsAg
and tumor number > 2 were significant different in uni-
variate analysis. The unadjusted OR (95% confidence
interval [CI]) was 0.337 (0.126 - 0.890) and 3.114 (1.088
- 8.867), respectively (P = 0.025 and 0.032). However, in
multivariate logistic regression analysis, only the presence
of HBsAg remained significantly correlated with CD133
expression. The adjusted OR (95% CI) was 0.084 (0.010 -
0.707) (P = 0.023). Therefore, CD133 expression was neg-
atively associated with the presence of HBsAg and the
association was independent of other factors.
Western blot analysis of p53 expression in HCC
The cancerous and non-cancerous liver tissues were also
subjected for Western blot analysis to detect p53 expres-
sion (Figure 4). Two major patterns were observed. In 129
patients, a small amount of p53 was detected in non-can-
cerous parts of liver tissues, whereas none (or only a trace
amount) was detected in the cancerous parts of liver tis-
sues (Figure 4A). In the remaining 25 patients, the
amount of p53 in the cancerous part was greater or equal
to that in the non-cancerous part (Figure 4B). Univariate
analysis showed that only male gender and the presence
of HBsAg were significantly correlated with p53 over-
expression in HCC (Table 3). The unadjusted OR (95%
CI) was 4.802 (1.019 - 31.022) and 4.203 (1.110 -
18.673), respectively (P = 0.046 and 0.031). However, in
multivariate logistic regression model, these two factors
were not appeared to be independent factors. CD133
expression was not associated with p53 expression in
HCC.
CD133 and p53 independently predict disease-free survival 
in HCC patients
Survival analysis indicated that patients with CD133
expression in HCC were significantly associated with poor
disease-free survival (Figure 5, left). The mean (95% CI)
disease-free survival time was 13.2 (8.2 - 18.3) and 40.0
(30.5 - 49.6) months respectively for patients with and
without CD133 expression in HCC (P = 0.009). Addition-
ally, CD133 expression also significantly associated with
poor overall survival (Figure 5, right). The mean (95% CI)
overall survival time was 32.2 (23.0 - 41.4) and 95.7 (83.7
- 107.8) months respectively for patients with and with-
out CD133 expression in HCC (P = 0.001).
Over-expression of p53 in HCC was also significantly
associated with poor disease-free survival (Figure 6). The
mean (95% CI) disease-free survival time was 15.0 (5.6 -
24.5) and 40.9 (31.3 - 50.5) months respectively for
patients with and without p53 over-expression in HCC (P
= 0.001). However, p53 expression was not associated
with overall survival. The mean (95% CI) overall survival
time was 81.9 (56.8 - 106.9) and 87.6 (75.0 - 100.3)
months respectively for patients with and without p53
over-expression in HCC (P = 0.606).
When the two factors were combined. It was found that
patients negative for both p53 and cd133 expression in
HCC have significantly better disease free-survival than
those with only positive p53 expression (P < 0.001), only
positive CD133 expression (P = 0.001), and both p53 and
CD133 expression (P = 0.006). Although the case number
Immunohistochemistry analysis of CD133 expression in  HCC in patient-16 Figure 3
Immunohistochemistry analysis of CD133 expression 
in HCC in patient-16. Original magnification, 200×.BMC Cancer 2009, 9:324 http://www.biomedcentral.com/1471-2407/9/324
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in the p53(+)/CD133(+) group was small, the survival dif-
ference between this group and the p53(-)/CD133(-)
group was large. As a result, the P value was significant
(Figure 6, right). The mean (95% CI) overall survival time
for these four groups of patients was 47.1 (35.8 - 58.4),
11.3 (5.8 - 16.8), 13.0 (8.0 - 18.0), and 3.5 (0.6 - 6.4)
months, respectively.
In Cox proportional hazard analysis using only p53 and
CD133 expression as covariates, it was found that the two
factors were independent factors for disease-free survival.
The hazard ratios (95% CI) were 1.697 (1.318 - 2.185)
and 2.559 (1.519 - 4.313), respectively (P < 0.001 for
both). In Cox proportional hazard analysis using all clin-
icopathological parameters, p53 expression, and CD133
expression as covariates, it was found that only p53
expression, tumor number, and AST remained to be sig-
nificant predictors for disease-free survival. The hazard
ratios (95% CI) were 1.827 (1.288 - 2.591), 1.754 (1.244
- 2.473), and 1.004 (1.001 - 1.008), respectively (P =
0.001, 0.001, and 0.008).
Discussion
In recent years, several putative tissue-restricted stem cell
markers were identified in their tumor counterparts
[18,30,31]. For example, CD34+CD38- cells in leukemia,
CD44+CD24low/lin- cells in breast cancer and CD133+ cells
in brain and prostate tumors [17,18,22-29]. A minor sub-
population of cancer cells possessing these markers was
found to exert high tumorigenicity in mice xenograft assay
[28]. In human liver, when massive necrosis and rigorous
regeneration occurred, CD133 could co-expressed with c-
Kit on the surface of putative hepatic progenitor cells [40].
Several studies subsequently discovered that a small pop-
ulation of CD133-positive cells was present in hepatob-
lastoma as well as HCC, raising the possibility that liver
cancer was of stem cell origin [34-36].
HCC expressed some de-differentiation markers, which
were also present in fetal liver, such as AFP and CK19.
Expression of these markers in HCC was associated with
higher tumor grade and shorter survival. Similarly,
CD133 expression was also associated with poorer prog-
Table 2: Multivariate logistic regression analysis of clinical parameters associated with CD133 expression in HCC.








Age (years) 53.6 ± 15.3 56.7 ± 14.9 0.983 (0.959 - 1.010) 0.997 (0.943 - 1.055)
Sex (male) 18 (75.0%) 96 (74.8%) 1.063 (0.358 - 3.282) 0.621 (0.109 - 3.542)
HBsAg (positive) 11 (45.8%) 93 (71.5%) 0.337 (0.126 - 0.890)c 0.084 (0.010 - 0.707)d
Anti-HCV (positive) 6 (25.0%) 36 (27.7%) 0.870 (0.283 - 2.575) 0.295 (0.027 - 3.192)
Cirrhosis (yes) 11 (45.8%) 62 (47.7%) 0.928 (0.356 - 2.410) 1.630 (0.324 - 8.188)
Alcoholism (yes) 6 (25.0%) 37 (28.5%) 0.838 (0.272 - 2.474) 1.135 (0.212 - 6.061)
Creatinine (mg/dL) 1.0 ± 0.2 1.3 ± 1.6 0.324 (0.048 - 2.202) 0.849 (0.167 - 4.305)
Tumor characteristics
Microvascular invasion (yes) 11 (45.8%) 35 (26.9%) 2.297 (0.862 - 6.110) 10.560 (1.312 - 84.994)
Edmondson's grading (> 2) 18 (75.0%) 77 (59.2%) 2.065 (0.710 - 6.271) 6.315 (0.758 - 52.618)
Encapsulation (yes) 17 (70.8%) 99 (76.2%) 0.760 (0.265 - 2.243) 1.775 (0.285 - 11.055)
Tumor number (> 2) 9 (37.5%) 21 (16.2%) 3.114 (1.088 - 8.867)e 2.933 (0.561 - 15.334)
Microsatellites (yes) 7 (29.2%) 20 (15.4%) 2.265 (0.740 - 6.794) 2.032 (0.185 - 22.347)
Tumor size (Diameter, cm) 8.0 ± 5.2 6.7 ± 4.6 1.057 (0.970 - 1.152) 0.881 (0.700 - 1.110)
Portal Vein Thrombosis (yes) 3 (12.5%) 10 (7.7%) 1.741 (0.341 - 7.616) 0.893 (0.094 - 8.487)
Alpha-fetoprotein (100 ng/mL) 70.3 ± 394.6 31.3 ± 55.6 1.000 (0.997 - 1.002) 0.996 (0.988 - 1.003)
Liver Function
Albumin (g/dL) 3.7 ± 0.6 3.8 ± 0.7 0.881 (0.446 - 1.742) 1.493 (0.409 - 5.456)
Bilirubin (mg/dL) 1.2 ± 0.9 1.3 ± 1.8 0.950 (0.688 - 1.310) 1.032 (0.588 - 1.812)
Prothrombin time (sec) 12.2 ± 1.2 12.5 ± 1.6 0.876 (0.623 - 1.232) 0.905 (0.563 - 1.456)
Ascites (yes) 2 (8.3%) 12 (9.2%) 0.894 (0.129 - 4.693) 1.140 (0.103 - 12.576)
Liver necroinflammation
AST (U/L) 117.3 ± 202.2 91.1 ± 98.3 1.002 (0.998 - 1.005) 1.009 (0.998 - 1.019)
ALT (U/L) 72.3 ± 116.9 75.6 ± 91.9 1.000 (0.995 - 1.005) 0.997 (0.987 - 1.007)
aUnadjusted odds ratios were calculated using regression analysis for parametric data and chi-square test for categorical data.
bOdds ratios adjusted for all other variables in this table; cP = 0.025; dP = 0.023; eP = 0.032.BMC Cancer 2009, 9:324 http://www.biomedcentral.com/1471-2407/9/324
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nosis [35,36]. At present, it is unclear whether CD133 was
a de-differentiation marker, which was expressed during
the process of oncogenic transformation from mature
hepatocytes to poorly differentiated cancer cells or alter-
natively, CD133-positive HCCs represent a subgroup of
liver cancers which were of stem cell origin.
In Southeast Asia including Taiwan, a great majority of
HCC patients were causatively associated with hepatitis B
virus infection [2]. Chronic viral hepatitis leads to perpet-
uated necroinflammation of the liver and thus continu-
ous regeneration of hepatocytes. Consequently, liver
cirrhosis occurred and HCC emerged. Presumably, liver
stem cells played a pivotal role in hepatocyte regeneration
and were prone to accumulating mutations on the target
genes, which resulted in malignant transformation. To the
contrary, in the present data, CD133 expression was neg-
atively associated with the presence of serum HBsAg in
both univariate and multivariate analysis. In contrast, p53
Table 3: Multivariate logistic regression analysis of clinical parameters associated with p53 over-expression in HCC.








Age (years) 52.5 ± 14.8 56.8 ± 15.0 0.985 (0.958 - 1.013) 0.995 (0.942 - 1.050)
Sex (male) 23 (92.0%) 91 (70.5%) 4.802 (1.019 - 31.022)c 10.217 (0.861 - 121.307)
HBsAg (positive) 22 (88.0%) 82 (63.6%) 4.203 (1.110 - 18.673)d 1.490 (0.130 - 17.10)
Anti-HCV (positive) 4 (16.0%) 38 (29.5%) 0.456 (0.123 - 1.537) 0.791 (0.074 - 8.490)
Cirrhosis (yes) 14 (56.0%) 59 (45.7%) 1.510 (0.590 - 3.893) 1.639 (0.396 - 6.783)
Alcoholism (yes) 5 (20.0%) 38 (29.5%) 0.599 (0.182 - 1.857) 0.269 (0.052 - 1.390)
Creatinine (mg/dL) 1.0 ± 0.2 1.2 ± 1.0 0.614 (0.193 - 1.954) 0.106 (0.003 - 4.139)
Tumor characteristics
Microvascular invasion (yes) 10 (40.0%) 36 (27.9%) 1.722 (0.647 - 4.547) 1.658 (0.249 - 11.043)
Edmondson's grading (> 2) 15 (60.0%) 93 (72.1%) 0.581 (0.220 - 1.545) 1.800 (0.404 - 8.019)
Encapsulation (yes) 18 (72.0%) 98 (76.0%) 0.813 (0.286 - 2.381) 0.600 (0.097 - 3.691)
Tumor number (> 2) 4 (16.0%) 26 (20.2%) 0.755 (0.200 - 2.609) 0.566 (0.080 - 4.008)
Microsatellites (yes) 3 (12.0%) 24 (18.6%) 0.597 (0.130 - 2.349) 2.520 (0.213 - 29.798)
Tumor size (Diameter, cm) 9.3 ± 9.5 6.9 ± 4.7 1.008 (0.920 - 1.104) 0.781 (0.590 - 1.034)
Portal Vein Thrombosis (yes) 6 (24.0%) 53 (41.1%) 0.453 (0.150 - 1.308) 4.645 (0.368 - 58.611)
Alpha-fetoprotein (100 ng/mL) 10.2 ± 27.5 62.0 ± 323.9 0.995 (0.982 - 1.008) 0.991 (0.967 - 1.016)
Liver Function
Albumin (g/dL) 3.7 ± 0.7 3.8 ± 0.7 0.860 (0.436 - 1.699) 2.560 (0.644 - 10.184)
Bilirubin (mg/dL) 1.2 ± 0.8 1.3 ± 1.8 0.950 (0.688 - 1.310) 0.591 (0.273 - 1.283)
Prothrombin time (sec) 12.5 ± 1.9 12.4 ± 1.5 1.049 (0.798 - 1.379) 1.146 (0.752 - 1.745)
Ascites (yes) 3 (12.0%) 11 (8.5%) 1.463 (0.296 - 6.358) 4.545 (0.613 - 33.665)
Liver necroinflammation
AST (U/L) 132.0 ± 210.7 88.7 ± 89.0 1.002 (0.999 - 1.006) 1.017 (1.005 - 1.030)
ALT (U/L) 90.4 ± 127.8 74.1 ± 91.0 1.001 (0.996 - 1.005) 0.985 (0.972 - 0.999)
CD133 expression 2 (8.0%) 22 (17.1%) 0.423 (0.064 - 2.064) 0.537 (0.055 - 5.202)
aUnadjusted odds ratios were calculated using regression analysis for parametric data and chi-square test for categorical data.
bOdds ratios adjusted for all other variables in this table;.
cP = 0.046; dP = 0.031
Western blot analysis of p53 in paired cancerous (T) and  adjacent non-cancerous (N) liver tissues Figure 4
Western blot analysis of p53 in paired cancerous (T) 
and adjacent non-cancerous (N) liver tissues. (A) p53 
was either undetectable or barely detected (patient-9 and 
14) in the cancerous tissues. (B) p53 was clearly detectable in 
the cancerous liver tissues.BMC Cancer 2009, 9:324 http://www.biomedcentral.com/1471-2407/9/324
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expression was positively associated with the presence of
HBsAg in univariate analysis. Therefore, it was revealed for
the first time that CD133 expression occurred more fre-
quently in HCCs unrelated to HBV infection. The present
data argued against a cancer-stem-cells origin of HBV-
related HCC and the CD133-positive HCCs appeared to
be a distinct subset of liver cancer not originated from
chronic HBV infection.
One of the most frequently reported genetic alterations in
human cancers was p53 gene mutation. Wild-type p53 is
believed to be a tumor suppressor, which inhibits tumor
growth when expressed. Its mutated forms however, exert
a dominant negative function and acts like an oncogene.
As a result, cancers expressing high level of mutated p53
tend to be more aggressive and associated with poor prog-
nosis [37,38]. Although we did not sequence the p53 gene
in this study, a previous report indicated that p53 muta-
tions in HCC were commonly seen in Taiwanese patients
[41]. Consistent with previous studies, the present results
also indicated that p53 over-expression was associated
with shorter disease-free survival. Importantly, in Cox
Disease-free (left panel) and overall (right panel) survivals in patients with or without CD133 expression in HCC Figure 5
Disease-free (left panel) and overall (right panel) survivals in patients with or without CD133 expression in 
HCC.
Prediction of disease-free survival using p53 over-expression alone (left panel) or using both p53 and CD133 expression (right  panel) in HCC Figure 6
Prediction of disease-free survival using p53 over-expression alone (left panel) or using both p53 and CD133 
expression (right panel) in HCC.BMC Cancer 2009, 9:324 http://www.biomedcentral.com/1471-2407/9/324
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proportional hazard model including all clinicopatholog-
ical covariates for analysis, p53 was one of the independ-
ent predictors. In contrast, CD133 was not a significant
predictor in this model, suggesting that other clinico-
pathological predictors were associated with CD133
expression. Finally, Cox proportional hazard model
clearly indicated that CD133 and p53 were two independ-
ent predictors for disease-free survival in HCC. This result
demonstrated for the first time that oncogenesis of the
putative stem-cell-originated HCCs likely involved path-
ways independent of p53 mutations.
Conclusion
Our present data indicated that in an area endemic for
HBV infection, HCCs positive for either p53 or CD133
expression were detected in a small but substantial pro-
portion of patients (16.2% and 15.6%). These two mark-
ers independently predicted shorter disease-free survival,
suggesting that growth of CD133-positive HCC involved
a pathway independent of p53 mutation. Furthermore,
CD133 expression was negatively associated with the
presence of serum HBsAg in our patients, arguing against
a stem cell origin of HBV-related HCC. The present results
implicated that CD133-positive HCC was a subset of liver
cancer not originated from chronic HBV infection but
originated from putative "cancer stem cells".
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